News and Trends 5 May 2023 Convergent Therapeutics to use $90M funding to treat cancer with radiopharmaceuticals Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the completion of a $90 million Series A financing. The funding was led by OrbiMed and RA Capital Management with participation from Invus. The financing will support the development of a pipeline of novel […] May 5, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 May 2023 Osteoporosis drug helps T cells fight aggressive breast cancer Researchers in Germany have discovered a mechanism by which cancer cells escape the immune system – and how to reverse it. Triple-negative breast cancer (TNBC) is the most aggressive and deadly form of breast cancer, with limited treatment options and a high probability of recurrence. Tumor growth and relapse of TNBC are driven by breast […] May 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 May 2023 LIfT BioSciences says data show potent killing of pancreatic cancer tumoroids LIfT BioSciences has revealed preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMAN) showed potent killing of pancreatic cancer tumoroids. The tumoroid originated from a patient with pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The patient was unresponsive to conventional chemotherapy treatment with Abraxane (nab-paclitaxel), but initially responded positively to […] May 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2023 Eterna acquires allogeneic immuno-oncology platform from Exacis Eterna Therapeutics Inc. has announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition complements Eterna Therapeutics’ core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna Therapeutics with an exclusive global license to produce an unlimited number of mRNA-engineered […] May 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 3 May 2023 Immunotherapy in the fight against solid tumors Ever since William Coley first attempted to harness the immune system in 1891 to treat bone cancer, immunotherapy has been explored in the treatment of various different cancers – both solid and liquid – and has revolutionized and rejuvenated the field of oncology. However, despite certain immunotherapy treatments having shown very promising results, such as […] May 3, 2023 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2023 FDA fast track for Memo’s kidney transplant infection treatment Memo Therapeutics AG, a biotech company developing therapeutic antibodies, says the U.S. Food and Drug Administration (FDA) has granted fast track designation to AntiBKV, Memo Therapeutics’ lead antibody therapeutic that targets BK polyomavirus (BKV) infection commonly seen in renal transplant patients. AntiBKV has successfully completed a phase I clinical study and following FDA clearance has […] May 2, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2023 Brenus Pharma reveals ‘groundbreaking’ preclinical results for colorectal cancer and solid tumor drug Brenus Pharma has announced what it said are two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma’s STC (stimulated tumor-cells) technology platform. Innovative models for anti-tumor vaccine development were highlighted: Inovotion’s CAM (chorioallantoic model) in-ovo assay and Explicyte’s ex-vivo co-cultured assay, were used to characterize the […] April 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Apr 2023 Progress in battle against stomach cancer Researchers at Ludwig-Maximilians-Universität München (LMU) in Germany have discovered a weakness in the bacterium Helicobacter pylori, which could be exploited to develop new drugs.H. pylori, a pathogen responsible for widespread illnesses such as gastric ulcers and stomach cancer, has a weak point, which could be exploited to create new drugs. This was discovered by a […] April 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 26 Apr 2023 Can mRNA vaccines tackle multiple diseases? By Dr. Myriam Mendila, chief development officer of CureVac World Immunization Week is April 24-30, and it’s an important week to highlight the action needed and to promote the use of vaccines to protect people around the world, of all ages, against infectious diseases. World Immunization Week aims to promote the use of vaccines to […] April 26, 2023 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2023 Gene therapy and chemotherapy could be new osteosarcoma treatment option New research has identified a potential therapeutic target and developed a unique delivery system to treat osteosarcoma, a bone cancer that primarily affects children and adolescents. The standard-of-care treatment plan for osteosarcoma today is no different to when first introduced almost 50 years ago. However, nearly one third of patients’ relapse and need new interventions. […] April 25, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2023 RNA-based nanodrugs cause cancer cells to collapse – 80% survival rate for ovarian cancer in lab models Researchers from Tel Aviv University in Israel have revealed details of a new approach to the treatment of ovarian cancer using RNA-based nanodrugs – demonstrating an 80% survival rate in lab models.In a study at Tel Aviv University, the protein CKAP5 (cytoskeleton-associated protein) was used for the first time as a therapeutic target for RNA-based […] April 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2023 New discovery “an area of cancer research with tremendous promise for breakthroughs” A research team led by Gary Ying Wai Chan from the School of Biological Sciences at The University of Hong Kong (HKU), has revealed the function of a unique enzyme, ANKLE1. ANKLE1 acts on chromatin bridges trapped in the midzone of dividing cells. By cutting these bridges, ANKLE1 prevents damage to the genetic material and […] April 21, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email